Software Effective Solutions Corp. (SFWJ) Strengthening Cannabis Foothold as CSA Status Set to Change
- An overwhelming share of U.S. adults say marijuana should be legal for medical or recreational use, reports Pew Research Center
- The U.S. attorney general has submitted official notice to begin the process of moving marijuana from a Schedule 1 to Schedule 3 drug under the Controlled Substances Act
- MedCana is committed to building the technology, laboratories, growing facilities and scientific teams to provide premium pharmaceutical-grade cannabis extracts
With a significant majority of Americans supporting cannabis use and the U.S. government on the verge of changing the status of the substance under the Controlled Substances Act (“CSA”), Software Effective Solutions (d/b/a MedCana) (OTC: SFWJ) is positioning itself for marked growth and success in the coming months. The company’s goal is to be the world’s premier resource for pharmaceutical cannabis products.
“As more states pass laws legalizing marijuana for recreational use, Americans continue to favor legalization of both medical and recreational use of the drug,” revealed a recent Pew Research Center survey (https://nnw.fm/RFO92 ). “An overwhelming share of U.S. adults (88%) say marijuana should be legal for medical or recreational use.
“Nearly six in ten Americans (57%) say that marijuana should be legal for medical and recreational purposes, while roughly a third (32%) say that marijuana should be legal for medical use only,” the report continued. “Just 11% of Americans say that the drug should not be legal at all.”
After many years, the federal government is seemingly catching up to public opinion. In May the Justice Department announced that the attorney general had submitted official notice to begin the process of considering moving marijuana from a Schedule 1 to Schedule 3 drug under the CSA (https://nnw.fm/ZZDek ).
“Marijuana has been classified as a Schedule 1 drug since Congress enacted the CSA in 1970,” the announcement noted. “On Oct. 6, 2022, President Biden asked the attorney general and the secretary of Health and Human Services (‘HHS’) to launch a scientific review of how marijuana is scheduled under federal law. After receiving HHS’s recommendations last August, the attorney general sought the legal advice of the Justice Department’s Office of Legal Counsel (‘OLC’) on questions relevant to this rulemaking. In light of HHS’s medical and scientific determinations, and OLC’s legal advice, the attorney general exercised his authority under the law to initiate the rulemaking process to transfer marijuana to Schedule 3.”
The process to make the change includes several steps, including a public comment period and final judicial review. “Still, the reclassification of cannabis would mark a new era in America’s often contradictory relationship with a substance already legalized in one form or another in more than half the states,” stated an article in The Week (https://nnw.fm/YgMaA ).
The Week noted that perhaps the most significant change reclassification would bring would be increasing governmental ability to conduct further research into the health benefits of cannabis. The article stated that “reclassification also means the government acknowledges cannabis, like all other Schedule 3 substances, has an ‘accepted medical use and may lawfully be dispensed by prescription,’ the Congressional Research Service said. However, any such prescriptions must be approved by the Food and Drug Administration.
“Beyond expanding and easing access to federal research opportunities, reclassifying cannabis will have a major impact on the booming — but still legally murky — marijuana industry as a whole,” the article observed.
With these looming changes as a backdrop, MedCana’s commitment to building the technology, laboratories, growing facilities and scientific teams needed to provide premium pharmaceutical-grade cannabis extracts to the world is perfectly timed. Committed to absolute integrity, sustainability and social responsibility, MedCana is a holding company focused on developing companies in the agricultural-technology and the cannabis industries. As MedCana moves forward with its expansion plans, the company remains committed to delivering on its promise of building a solid foundation for future growth of its holdings.
For more information, visit the company’s website at www.MedCana.net.
NOTE TO INVESTORS: The latest news and updates relating to SFWJ are available in the company’s newsroom at https://nnw.fm/SFWJ
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
- An overwhelming share of U.S. adults say marijuana should be legal for medical or recreational use, reports Pew Research Center
- The U.S. attorney general has submitted official notice to begin the process of moving marijuana from a Schedule 1 to Schedule 3 drug under the Controlled Substances Act
- MedCana is committed to building the technology, laboratories, growing facilities and scientific teams to provide premium pharmaceutical-grade cannabis extracts
With a significant majority of Americans supporting cannabis use and the U.S. government on the verge of changing the status of the substance under the Controlled Substances Act (“CSA”), Software Effective Solutions (d/b/a MedCana) (OTC: SFWJ) is positioning itself for marked growth and success in the coming months. The company’s goal is to be the world’s premier resource for pharmaceutical cannabis products.
“As more states pass laws legalizing marijuana for recreational use, Americans continue to favor legalization of both medical and recreational use of the drug,” revealed a recent Pew Research Center survey (https://nnw.fm/RFO92 ). “An overwhelming share of U.S. adults (88%) say marijuana should be legal for medical or recreational use.
“Nearly six in ten Americans (57%) say that marijuana should be legal for medical and recreational purposes, while roughly a third (32%) say that marijuana should be legal for medical use only,” the report continued. “Just 11% of Americans say that the drug should not be legal at all.”
After many years, the federal government is seemingly catching up to public opinion. In May the Justice Department announced that the attorney general had submitted official notice to begin the process of considering moving marijuana from a Schedule 1 to Schedule 3 drug under the CSA (https://nnw.fm/ZZDek ).
“Marijuana has been classified as a Schedule 1 drug since Congress enacted the CSA in 1970,” the announcement noted. “On Oct. 6, 2022, President Biden asked the attorney general and the secretary of Health and Human Services (‘HHS’) to launch a scientific review of how marijuana is scheduled under federal law. After receiving HHS’s recommendations last August, the attorney general sought the legal advice of the Justice Department’s Office of Legal Counsel (‘OLC’) on questions relevant to this rulemaking. In light of HHS’s medical and scientific determinations, and OLC’s legal advice, the attorney general exercised his authority under the law to initiate the rulemaking process to transfer marijuana to Schedule 3.”
The process to make the change includes several steps, including a public comment period and final judicial review. “Still, the reclassification of cannabis would mark a new era in America’s often contradictory relationship with a substance already legalized in one form or another in more than half the states,” stated an article in The Week (https://nnw.fm/YgMaA ).
The Week noted that perhaps the most significant change reclassification would bring would be increasing governmental ability to conduct further research into the health benefits of cannabis. The article stated that “reclassification also means the government acknowledges cannabis, like all other Schedule 3 substances, has an ‘accepted medical use and may lawfully be dispensed by prescription,’ the Congressional Research Service said. However, any such prescriptions must be approved by the Food and Drug Administration.
“Beyond expanding and easing access to federal research opportunities, reclassifying cannabis will have a major impact on the booming — but still legally murky — marijuana industry as a whole,” the article observed.
With these looming changes as a backdrop, MedCana’s commitment to building the technology, laboratories, growing facilities and scientific teams needed to provide premium pharmaceutical-grade cannabis extracts to the world is perfectly timed. Committed to absolute integrity, sustainability and social responsibility, MedCana is a holding company focused on developing companies in the agricultural-technology and the cannabis industries. As MedCana moves forward with its expansion plans, the company remains committed to delivering on its promise of building a solid foundation for future growth of its holdings.
For more information, visit the company’s website at www.MedCana.net.
NOTE TO INVESTORS: The latest news and updates relating to SFWJ are available in the company’s newsroom at https://nnw.fm/SFWJ
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
